No Fluff. Just Sources.
Pipeline Deep Dive

Survodutide: Boehringer's GLP-1/Glucagon Dual Agonist Improved MASH in 83% of Patients

Survodutide targets both GLP-1 and glucagon receptors — the same glucagon component that makes retatrutide unique, but without the GIP receptor. Phase 2 data published in NEJM showed 83% improvement in MASH, 87% achieved major liver fat reduction, and 64.5% improved fibrosis. Phase 3 trials are underway for both liver disease and obesity.

Published May 2026 · Sources verified May 2026

Boehringer Ingelheim's survodutide occupies a distinct position in the next-generation GLP-1 pipeline. Unlike tirzepatide (GLP-1 + GIP) or retatrutide (GLP-1 + GIP + glucagon), survodutide pairs GLP-1 with glucagon receptor agonism while omitting GIP. The rationale: glucagon's direct effects on hepatic lipid metabolism make it uniquely suited for liver disease, and clinical data from the Phase 2 MASH trial suggests this bet is paying off.

The results, published in the New England Journal of Medicine in July 2024 and presented at EASL 2024, showed MASH improvement rates that exceeded every other drug tested in this population to date. Boehringer is now running five Phase 3 trials for obesity and an additional Phase 3 for MASH.

83% Patients achieving histologic improvement in MASH with no worsening of fibrosis at 48 weeks (survodutide 4.8 mg, actual treatment analysis). NEJM 2024.

The Phase 2 MASH Trial

The Phase 2 trial enrolled 293 adults with biopsy-confirmed MASH and fibrosis stages F1 through F3. Participants were randomized 1:1:1:1 to once-weekly survodutide at 2.4 mg, 4.8 mg, or 6.0 mg, or placebo, for 48 weeks (24-week escalation + 24-week maintenance).

Endpoint (48 wk, actual treatment) 2.4 mg 4.8 mg 6.0 mg Placebo
MASH improvement, no fibrosis worsening 47% 62% 43% 14%
MASH resolution, no fibrosis worsening 75% 15%
Liver fat reduction ≥30% 63% 67% 87% 14%
Fibrosis improvement ≥1 stage (F2/F3) Up to 64.5% Low
Relative liver fat reduction −64.3% −7.3%

The 6.0 mg dose showed the highest MASH improvement rate of 83% (including nonresponders), though the dose-response was not perfectly linear — the 4.8 mg dose performed well on most endpoints. The fibrosis data is particularly notable: 64.5% of patients with clinically significant fibrosis (F2/F3) improved by at least one stage.

Why Glucagon Matters for the Liver

Glucagon receptor activation directly stimulates hepatic fatty acid oxidation — literally telling the liver to burn its stored fat. This mechanism is distinct from GLP-1's indirect effects (weight loss → reduced liver fat) and may explain why survodutide's liver fat reduction results are so striking. The 6.0 mg group achieved a 64.3% relative reduction in liver fat versus 7.3% with placebo.

The tradeoff with glucagon agonism is potential glycemic effects: glucagon raises blood glucose. In survodutide, the GLP-1 component counterbalances this by stimulating insulin secretion. The Phase 2 data showed no significant glycemic worsening, but this balance will need to be carefully monitored in larger Phase 3 populations that include more patients with type 2 diabetes.

Where Survodutide Fits in the Pipeline

Boehringer Ingelheim is running five Phase 3 obesity trials and a dedicated Phase 3 MASH trial with fibrosis endpoints. If successful, survodutide could be the first GLP-1/glucagon dual agonist approved for either indication. It competes with retatrutide (triple agonist, Lilly), semaglutide (ESSENCE trial for MASH), and pemvidutide (Altimmune, GLP-1/glucagon for liver disease) in a rapidly crowding liver/obesity intersection.

What We Don't Know Yet

Phase 2 enrolled 293 patients for 48 weeks. Phase 3 will provide data on long-term safety, cardiovascular outcomes, and whether the MASH improvement translates to reduced cirrhosis progression and liver-related mortality. The non-linear dose response (6.0 mg was not consistently superior to 4.8 mg on all endpoints) needs clarification in larger trials. Survodutide is investigational and not approved for any use.

Sources

  1. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. DOI: 10.1056/NEJMoa2401755. NEJM
  2. Boehringer Ingelheim. Phase II results presented at EASL 2024. June 2024. boehringer-ingelheim.com
  3. Boehringer Ingelheim. Survodutide Phase II topline results press release. February 26, 2024.